The online version of this article (doi:10.1186/1471-2261-14-129) contains supplementary material, which is available to authorized users.
RTI Health Solutions employees work on projects funded by pharmaceutical companies including manufacturers of treatments for patients with diabetes. As employees of RTI Health Solutions, Manel Pladevall, Susana Perez-Gutthann, and Cristina Varas-Lorenzo also participate in advisory boards funded by pharmaceutical companies. Lorna Hazell is an employee of the Drug Safety Research Unit, an organization that has received unconditional research grants from companies that manufacture drugs used in the treatment of diabetes, although none of these are related to this study. The authors declare that they have no competing interests.
CVL, MP, NRG, LH and SPG participated in the development of the literature search strategy; MP, NRG, and AM abstracted and compiled the data; NRG, BC, AM, MP and CVL performed the analyses; all authors oversaw design of the study and facilitated interpretation of the findings. CVL and AM drafted the manuscript; and all of the coauthors have been revising it critically for important intellectual content, read and approved the final manuscript. All authors had full access to all of the abstracted data from published studies included in this systematic review and take responsibility for the integrity of summarizing the data and the accuracy of the meta-analysis. All authors read and approved the final manuscript.
Patients with type 2 diabetes mellitus (T2DM) are at high risk of heart failure. A summary of the effects of blood glucose-lowering drugs other than glitazones on the risk of heart failure in routine clinical practice is lacking. The objective of this study was to conduct a systematic review and meta-analysis of observational studies on the risk of heart failure when using blood glucose-lowering drugs.
We systematically identified and reviewed cohort and case–control studies in which the main exposure of interest was noninsulin blood glucose-lowering medications in patients with T2DM. We searched Medline, Embase, and the Cochrane Library to identify publications meeting prespecified eligibility criteria. The quality of included studies was assessed with the Newcastle-Ottawa Scale and the RTI item bank. Results were combined using fixed and random-effects models when at least 3 independent data points were available for a drug-drug comparison.
The summary relative risk of heart failure in rosiglitazone users versus pioglitazone users (95% CI) was 1.16 (1.05-1.28) (5 cohort studies). Heterogeneity was present (I 2 = 66%). For new users (n = 4) the summary relative risk was 1.21 (1.14-1.30) and the heterogeneity was reduced (I 2 = 31%);. The summary relative risk for rosiglitazone versus metformin was 1.36 (95% CI, 1.17-1.59) (n = 3). The summary relative risk (95% CI) of heart failure in sulfonylureas users versus metformin users was 1.17 (95% CI, 1.06-1.29) (5 cohort studies; I 2 = 24%) and 1.22 (1.02-1.46) when restricted to new users (2 studies).
Information on other comparisons was very scarce. Information on dose and duration of treatment effects was lacking for most comparisons. Few studies accounted for disease severity; therefore, confounding by indication might be present in the majority of the within-study comparisons of this meta-analysis.
Use of glitazones and sulfonylureas was associated with an increased risk of heart failure compared with metformin use. However, indication bias cannot be ruled out. Ongoing large multidatabase studies will help to evaluate the risk of heart failure in treated patients with diabetes, including those using newer blood glucose-lowering therapies.
Additional file 1: Online Appendix. Table S1e. Search Terms for Medline Search. Table S2e. Newcastle-Ottawa Scale Quality Assessment Results, Individual Case–control Studies. Table S3e. Newcastle-Ottawa Scale Quality Assessment Results, Individual Cohort Studies. Table S4e. RTI Item Bank Adapted to the Present Systematic Review. Table S5e. RTI Item Bank Quality Assessment Results, Individual Studies. Figure S1e. Heart Failure Relative Risk (Random Effects) in New Users: Rosiglitazone Compared With Pioglitazone. Figure S2e. Heart Failure Relative Risk (Random Effects) in Rosiglitazone Users Compared With Metformin Users, by Type of Regimen. Figure S3e. Heart Failure Relative Risk (Random Effects) in Sulfonylurea Users Compared With Metformin Users, by Type of Use. Figure S4e. Funnel Plot: Heart Failure Relative Risk for Rosiglitazone Users Compared With Pioglitazone Users (5 Studies). Figure S5e. Funnel Plot: Heart Failure Relative Risk for Sulfonylureas Users Compared With Metformin Users (5 Studies). MOOSE Checklist. (DOC 802 KB)
Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvänne M, Op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F: European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Int J Behav Med. 2012, 19: 403-488. 10.1007/s12529-012-9242-5. CrossRefPubMed
Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, De Boer MJ, Cosentino F, Jonsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, et al: Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007, 28: 88-136. CrossRefPubMed
US Food and Drug Administration: FDA requires removal of certain restrictions on the diabetes drug Avandia. November 25, 2013
Goyal A, Norton CR, Thomas TN, Davis RL, Butler J, Ashok V, Zhao L, Vaccarino V, Wilson PW: Predictors of incident heart failure in a large insured population: a one million person-year follow-up study. Circ Heart Fail. 2010, 3: 698-705. 10.1161/CIRCHEARTFAILURE.110.938175. CrossRefPubMedPubMedCentral
Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000, 321: 405-412. 10.1136/bmj.321.7258.405. CrossRefPubMedPubMedCentral
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR: Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012, 35: 1364-1379. 10.2337/dc12-0413. CrossRefPubMedPubMedCentral
US Food and Drug Administration: Information for healthcare professionals: pioglitazone HCl (marketed as Actos, Actoplus Met, and Duetact). 2007
Takeda Pharmaceuticals America, Inc: Actos (pioglitazone) tablets for oral use [package insert]. 2013
US Food and Drug Administration: FDA adds boxed warning for heart-related risks to anti-diabetes drug Avandia. November 14, 2007
GlaxoSmithKline: Avandia (rosiglitazone maleate) tablets [package insert]. 2007
Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, Vanderloo SE, McAlister FA: Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail. 2013, 6: 395-402. 10.1161/CIRCHEARTFAILURE.112.000162. CrossRefPubMed
Chen X, Yang L, Zhai SD: Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies. Chin Med J (Engl). 2012, 125: 4301-4306.
Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Block L, Nicholson WK, Hutfless S, Bass EB, Bolen S: Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011, 154: 602-613. 10.7326/0003-4819-154-9-201105030-00336. CrossRefPubMedPubMedCentral
Higgins JPT, Green S: Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0. Section 188.8.131.52. Tools for Assessing Methodological Quality or Risk of Bias in Non-randomized Studies. 2011, London: The Cochrane Collaboration
Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2011
Viswanathan M, Berkman ND: Development Of The RTI Item Bank On Risk Of Bias And Precision Of Observational Studies. 2011, Rockville (MD): Agency for Healthcare Research and Quality
The Cochrane Collaboration: Cochrane handbook for systematic reviews of interventions, version 5.1.0. March 2011
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB: Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000, 283: 2008-2012. 10.1001/jama.283.15.2008. CrossRefPubMed
Hsiao FY, Huang WF, Wen YW, Chen PF, Kuo KN, Tsai YW: Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan. Drug Saf. 2009, 32: 675-690. 10.2165/00002018-200932080-00006. CrossRefPubMed
Loebstein R, Dushinat M, Vesterman-Landes J, Silverman B, Friedman N, Katzir I, Kurnik D, Lomnicky Y, Kokia E, Halkin H: Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes. J Clin Pharmacol. 2011, 51: 173-180. 10.1177/0091270010368281. CrossRefPubMed
Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, Hughes RI, Khunti K, Wilkins MR, Majeed A, Elliott P: Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ. 2009, 339: b4731-10.1136/bmj.b4731. CrossRefPubMedPubMedCentral
Habib ZA, Tzogias L, Havstad SL, Wells K, Divine G, Lanfear DE, Tang J, Krajenta R, Pladevall M, Williams LK: Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis. Pharmacoepidemiol Drug Saf. 2009, 18: 437-447. 10.1002/pds.1722. CrossRefPubMedPubMedCentral
Hsiao FY, Tsai YW, Wen YW, Chen PF, Chou HY, Chen CH, Kuo KN, Huang WF: Relationship between cumulative dose of thiazolidinediones and clinical outcomes in type 2 diabetic patients with history of heart failure: a population-based cohort study in Taiwan. Pharmacoepidemiol Drug Saf. 2010, 19: 786-791. 10.1002/pds.1999. CrossRefPubMed
Rajagopalan R, Rosenson RS, Fernandes AW, Khan M, Murray FT: Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. Clin Ther. 2004, 26: 1400-1410. 10.1016/j.clinthera.2004.09.016. CrossRefPubMed
Margulis AV, Pladevall M, Riera-Guardia N, Varas-Lorenzo C, Hazell L, Berkman ND, Viswanathan M, Perez-Gutthann S: Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank. Clin Epidemiol. 2014, 6: 1-10.
Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I, SAVOR-TIMI 53 Steering Committee and Investigators: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013, 369: 1317-1326. 10.1056/NEJMoa1307684. CrossRefPubMed
Weir DL, McAlister FA, Senthilselvan A, Minhas-Sandhu JK, Eurich DT: Sitagliptin Use in Patients With Diabetes and Heart Failure: A Population-Based Retrospective Cohort Study. 2014, Europe: JACC Heart Fail
Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, Tan M, Spanheimer R, Standl E, Dormandy JA, investigators PR: Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care. 2007, 30: 2773-2778. 10.2337/dc07-0717. CrossRefPubMed
McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Task Force for the Diagnosis, Treatment of Acute, Chronic Heart Failure 2012 of the European Society of Cardiology, et al: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012, 14: 803-869. CrossRefPubMed
UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998, 352: 854-865. CrossRef
Gallagher AM, Smeeth L, Seabroke S, Leufkens HG, Van Staa TP: Correction: Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the General Practice Research Database and secondary care data. PLoS ONE. 2013, 8:
Breunig IM, Shaya FT, McPherson ML, Snitker S: Development of heart failure in medicaid patients with type 2 diabetes treated with pioglitazone, rosiglitazone, or metformin. J Manag Care Pharm. 2014, 20: 895-903.
Romero SP, Andrey JL, Garcia-Egido A, Escobar MA, Perez V, Corzo R, Garcia-Domiguez GJ, Gomez F: Metformin therapy and prognosis of patients with heart failure and new-onset diabetes mellitus. A propensity-matched study in the community. Int J Cardiol. 2013, 166: 404-412. 10.1016/j.ijcard.2011.10.141. CrossRefPubMed
Roussel R, Hadjadj S, Pasquet B, Wilson PW, Smith SC, Goto S, Tubach F, Marre M, Porath A, Krempf M, Bhatt DL, Steg PG: Thiazolidinedione use is not associated with worse cardiovascular outcomes: a study in 28,332 high risk patients with diabetes in routine clinical practice: brief title: thiazolidinedione use and mortality. Int J Cardiol. 2013, 167: 1380-1384. 10.1016/j.ijcard.2012.04.019. CrossRefPubMed
- The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies
Andrea V Margulis
- BioMed Central
Neu im Fachgebiet Kardiologie
Mail Icon II